Biovica International Future Growth
Future criteria checks 6/6
Biovica International is forecast to grow earnings and revenue by 73.8% and 73.4% per annum respectively. EPS is expected to grow by 86% per annum. Return on equity is forecast to be 28.7% in 3 years.
Key information
73.8%
Earnings growth rate
86.0%
EPS growth rate
| Biotechs earnings growth | 39.3% |
| Revenue growth rate | 73.4% |
| Future return on equity | 28.7% |
| Analyst coverage | Low |
| Last updated | 20 Jun 2024 |
Recent future growth updates
Recent updates
Is Biovica International (STO:BIOVIC B) In A Good Position To Deliver On Growth Plans?
Jul 18
Here's Why We're Watching Biovica International's (STO:BIOVIC B) Cash Burn Situation
Dec 02Here's Why We're Not Too Worried About Biovica International's (STO:BIOVIC B) Cash Burn Situation
Aug 02Here's Why We're Not At All Concerned With Biovica International's (STO:BIOVIC B) Cash Burn Situation
Feb 17A Look At The Intrinsic Value Of Biovica International AB (publ) (STO:BIOVIC B)
Jan 19Companies Like Biovica International (STO:BIOVIC B) Can Afford To Invest In Growth
Nov 11We Think Biovica International (STO:BIOVIC B) Can Easily Afford To Drive Business Growth
Aug 06We're Not Worried About Biovica International's (STO:BIOVIC B) Cash Burn
Mar 20Who Has Been Buying Biovica International AB (publ) (STO:BIOVIC B) Shares?
Feb 22What Kind Of Shareholders Hold The Majority In Biovica International AB (publ)'s (STO:BIOVIC B) Shares?
Jan 26The Biovica International (STO:BIOVIC B) Share Price Has Soared 349%, Delighting Many Shareholders
Dec 31
Here's Why We're Not At All Concerned With Biovica International's (STO:BIOVIC B) Cash Burn Situation
Dec 05Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 4/30/2027 | 232 | 25 | 46 | 48 | 1 |
| 4/30/2026 | 140 | -42 | 7 | 8 | 1 |
| 4/30/2025 | 42 | -70 | -66 | -65 | 1 |
| 4/30/2024 | 7 | -125 | -115 | -115 | N/A |
| 1/31/2024 | 7 | -123 | -119 | -119 | N/A |
| 10/31/2023 | 7 | -124 | -121 | -120 | N/A |
| 7/31/2023 | 6 | -122 | -118 | -116 | N/A |
| 4/30/2023 | 5 | -110 | -97 | -95 | N/A |
| 1/31/2023 | 6 | -92 | -85 | -82 | N/A |
| 10/31/2022 | 5 | -78 | -72 | -67 | N/A |
| 7/31/2022 | 5 | -69 | -59 | -56 | N/A |
| 4/30/2022 | 5 | -60 | -56 | -52 | N/A |
| 1/31/2022 | 3 | -53 | -47 | -44 | N/A |
| 10/31/2021 | 4 | -50 | -48 | -45 | N/A |
| 7/31/2021 | 7 | -43 | -43 | -40 | N/A |
| 4/30/2021 | 7 | -39 | -38 | -34 | N/A |
| 1/31/2021 | 9 | -38 | -39 | -35 | N/A |
| 10/31/2020 | 10 | -35 | -37 | -30 | N/A |
| 7/31/2020 | 10 | -33 | -36 | -28 | N/A |
| 4/30/2020 | 10 | -30 | -32 | -25 | N/A |
| 1/31/2020 | 12 | -25 | -29 | -20 | N/A |
| 10/31/2019 | 11 | -24 | -29 | -21 | N/A |
| 7/31/2019 | 10 | -24 | -26 | -19 | N/A |
| 4/30/2019 | 10 | -22 | -25 | -18 | N/A |
| 1/31/2019 | 10 | -20 | -25 | -17 | N/A |
| 10/31/2018 | 9 | -20 | -21 | -16 | N/A |
| 7/31/2018 | 9 | -19 | -23 | -15 | N/A |
| 4/30/2018 | 10 | -18 | -23 | -15 | N/A |
| 1/31/2018 | 9 | -20 | N/A | -14 | N/A |
| 10/31/2017 | 9 | -18 | N/A | -15 | N/A |
| 7/31/2017 | 8 | -16 | N/A | -14 | N/A |
| 4/30/2017 | 6 | -15 | N/A | -11 | N/A |
| 1/31/2017 | 6 | -11 | N/A | -14 | N/A |
| 10/31/2016 | 6 | -9 | N/A | -14 | N/A |
| 7/31/2016 | 7 | -7 | N/A | -10 | N/A |
| 4/30/2016 | 7 | -6 | N/A | -9 | N/A |
| 4/30/2015 | 4 | -7 | N/A | N/A | N/A |
| 4/30/2014 | 4 | -5 | N/A | N/A | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BIOVIC B is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1%).
Earnings vs Market: BIOVIC B is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: BIOVIC B is expected to become profitable in the next 3 years.
Revenue vs Market: BIOVIC B's revenue (73.4% per year) is forecast to grow faster than the Swedish market (1.7% per year).
High Growth Revenue: BIOVIC B's revenue (73.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BIOVIC B's Return on Equity is forecast to be high in 3 years time (28.7%)